+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07218315

Evaluation of Nanosecond Pulsed Field Ablation for Treating T1N0M0 Papillary Thyroid Carcinoma Using the CellFX System

Led by M.D. Anderson Cancer Center · Updated on 2026-09-11

15

Participants Needed

2

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of nanosecond pulsed field ablation nsPFA in treating patients with T1N0M0 papillary thyroid carcinoma PTC, a type of thyroid cancer. The study aims to measure changes in thyroid nodule volume, including volume reduction rate, technique efficacy, and nodule regrowth after the procedure. The research also assesses clinical safety, possible complications, and changes in ultrasound features and health-related quality of life over time. Participants will undergo an outpatient thyroid ablation using the CellFX nsPFA Percutaneous Electrode System. This procedure is performed under local anesthesia or intravenous sedation. The study involves a single treatment group receiving this device-based intervention to evaluate its impact on the thyroid nodules. Throughout the study, participants will have follow-up visits to monitor thyroid nodule volume changes and safety outcomes, including adverse events, for about one year on average. Researchers will use ultrasound evaluations and clinical assessments to track treatment effects and quality of life. The total study duration extends up to the study completion date, with ongoing monitoring as part of the follow-up period.

CONDITIONS

Brief Title

Nanosecond Pulsed Field Ablation in the Management of T1N0M0 Papillary Thyroid Carcinoma

Research Team

V

Victoria E Banuchi, MPH

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here